Deletion of Dystrophin In-Frame Exon 5 Leads to a Severe Phenotype: Guidance for Exon Skipping Strategies

PLoS One. 2016 Jan 8;11(1):e0145620. doi: 10.1371/journal.pone.0145620. eCollection 2016.

Abstract

Duchenne and Becker muscular dystrophy severity depends upon the nature and location of the DMD gene lesion and generally correlates with the dystrophin open reading frame. However, there are striking exceptions where an in-frame genomic deletion leads to severe pathology or protein-truncating mutations (nonsense or frame-shifting indels) manifest as mild disease. Exceptions to the dystrophin reading frame rule are usually resolved after molecular diagnosis on muscle RNA. We report a moderate/severe Becker muscular dystrophy patient with an in-frame genomic deletion of DMD exon 5. This mutation has been reported by others as resulting in Duchenne or Intermediate muscular dystrophy, and the loss of this in-frame exon in one patient led to multiple splicing events, including omission of exon 6, that disrupts the open reading frame and is consistent with a severe phenotype. The patient described has a deletion of dystrophin exon 5 that does not compromise recognition of exon 6, and although the deletion does not disrupt the reading frame, his clinical presentation is more severe than would be expected for classical Becker muscular dystrophy. We suggest that the dystrophin isoform lacking the actin-binding sequence encoded by exon 5 is compromised, reflected by the phenotype resulting from induction of this dystrophin isoform in mouse muscle in vivo. Hence, exon skipping to address DMD-causing mutations within DMD exon 5 may not yield an isoform that confers marked clinical benefit. Additional studies will be required to determine whether multi-exon skipping strategies could yield more functional dystrophin isoforms, since some BMD patients with larger in-frame deletions in this region have been reported with mild phenotypes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cells, Cultured
  • Child
  • Disease Models, Animal
  • Dystrophin / analysis
  • Dystrophin / genetics*
  • Exons
  • Humans
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Muscular Dystrophy, Duchenne / genetics*
  • Muscular Dystrophy, Duchenne / pathology
  • Oligonucleotides, Antisense / metabolism
  • Phenotype
  • RNA / chemistry
  • RNA / metabolism
  • RNA Splicing
  • Sequence Analysis, RNA
  • Sequence Deletion

Substances

  • Dystrophin
  • Oligonucleotides, Antisense
  • RNA

Grants and funding

This study was supported by the Muscular Dystrophy Association USA (272200), the National Health and Medical Research Council (1043758, 1055319, 1086311), Duchenne Ireland and Muscular Dystrophy Western Australia. DI and MDWA are special interest groups supporting muscular dystrophy research. Additionally, Sarepta Therapeutics provide the phosphorodiamidate morpholinos targeting mouse dystrophin exon 5. These funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.